Eine der wichtigsten Fragen bei der SARS-CoV-2 Pandemie ist, wie lange die Immunität, auch im Hinblick auf SARS-CoV-2 Mutationen, nach durchgemachter Infektion oder Impfung anhält. Darüber hinaus soll ermittelt werden, ob sich die Immunantwort nach einer SARS-CoV-2 Impfung von der nach einer Infektion unterscheidet. Dazu werden verschiedene Immunzellen, wie T-Zellen, B-Zellen und NK-Zellen sowie die Bildung von Antikörpern von SARS-CoV-2 Infizierten, COVID-19 Genesenen und Impflingen untersucht. Daneben soll untersucht werden, welchen Einfluss die Immunantwort auf den Verlauf der COVID-19 Erkrankung sowie auf die Entwicklung von Langzeitschäden hat. Die gewonnenen Erkenntnisse sollen dazu dienen, Medikamente und Therapien zu entwickeln, die Einfluss auf den Verlauf einer SARS-CoV-2 Infektion nehmen.

Publikationen im Rahmen des VIRAL Netzwerks:

2023

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.

Implementing the Lolli-Method and pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools: a pilot project

Influence of the Single Nucleotide Polymorphisms rs12252 and rs34481144 in IFITM3 on the Antibody Response after Vaccination against COVID-19.https://pubmed.ncbi.nlm.nih.gov/37515072/

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.

Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.

Antibody responses elicited by mRNA vaccination in firefighters persist six months and correlate inversely with age and directly with BMI.

SARS-CoV-2-specific T cell responses wane profoundly in convalescent individuals 10 months after primary infection.https://pubmed.ncbi.nlm.nih.gov/37414153/

COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.https://pubmed.ncbi.nlm.nih.gov/37006279/

Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2.  

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.

Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific  Reactivity in a Vaccination Cohort.

Factors Associated With Vaccine-Induced T-Cell Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Kidney Transplant Recipients.https://pubmed.ncbi.nlm.nih.gov/36408631/

Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication.

Macrophage migration inhibitory factor receptor CD74 expression is associated with expansion and differentiation of effector T cells in COVID-19 patients.https://pubmed.ncbi.nlm.nih.gov/37946732/

2022

Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages.

The Effect of Age on the Magnitude and Longevity of Th1‐directed CD4 T‑cell Responses to SARS‑CoV‑2

Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti‐SARS‐CoV‐2 Activity

Serological Markers of SARS-CoV-2 Reinfection

Immunogenicity of bivalent Omikron BA.4/5 adapted vaccine in hemodialysis patients

Significant fade of neutralizing antibodies and stable cellular immunity in 4 times COVID-19 vaccinated non-infected compared to COVID-19 convalescent and 3 times vaccinated hemodialysis patients

3D Ex vivo tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseases.

Inferior humoral and sustained cellular immunity against wild-type and Omikron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses

Inferior cellular and humoral immunity against Omikron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

Impact of low eGFR on the immune response against COVID-19

Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients

SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids

Viral Load Dynamics in SARS-CoV-2 Omikron Breakthrough Infections

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19

Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)

Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omikron variant

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

The effect of age on the magnitude and longevity of Th1-directed CD4 T-cell responses to SARS-CoV-2

Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection

Differential interferon-alpha subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection

2021

Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment.

Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.

Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.

SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response.

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients.

The effect of age on the magnitude and longevity of Th1-directed CD4 T-cell responses to SARS-CoV-2

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination.

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID‑19

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1

Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

Detectable SARS-CoV-2 RNAemia in Critically Ill Patients but Not in Mild and Asymptomatic Infections

SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

Correlation between a Quantitative Anti‐SARS‐CoV‐2 IgG ELISA and Neutralization Activity

Kontakt

Bei Fragen wenden Sie sich gern an

Dr. Martha Paluschinski
Dr. Anna-Kathrin Schupp

info@viral-nrw.de

oder nutzen Sie unser